搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
The Pharma Letter
1 天
BIOVIIIx unit deal with TagCyx to create new company
Naples, Italy-based rare diseases focused biotech BIOVIIIx says that its subsidiary Anbition and Japanese firm TagCyx ...
The Pharma Letter
1 天
ALX Oncology says evorpacept scores well in Phase II study
US clinical-stage immuno-oncology biotech ALX Oncology Holdings released positive updated data from the ASPEN-06 Phase II ...
The Pharma Letter
2 天
Novo Nordisk jumps on positive early trial with SC amycretin for obesity
Denmark’s Novo Nordisk saw its shares rise as much as 13% to 659.20 kroner this morning, after it announced top-line results ...
The Pharma Letter
2 天
FDA delays PDUFA action date for elamipretide
US clinical-stage drug developer Stealth BioTherapeutics announced that the US Food and Drug Administration (FDA) has ...
The Pharma Letter
2 天
Moderna secures second EU mRNA COVID-19 Vaccine tender
US vaccines developer Moderna today announced that it has been awarded a tender for the supply of its mRNA COVID-19 vaccine ...
The Pharma Letter
2 天
Neurocrine appoints Andrew Ratz as senior VP
Neurocrine Biosciences appoints Andrew Ratz as senior VP of drug development amid expanding R&D efforts. The move follows FDA ...
The Pharma Letter
2 天
RPD designation for Nippon Shinyaku’s DMD candidate
The US Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to NS-051/NCNP-04, which is ...
The Pharma Letter
2 天
AstraZeneca plans $570 million investment in Canada
Spreading its geographic wings further, in the face of ongoing difficulties in China, UK pharma major AstraZeneca has ...
The Pharma Letter
2 天
Vigil moves into Phase II with Alzheimer's pill
Vigil Neuroscience advances VG-3927, a small molecule TREM2 agonist, into Phase II Alzheimer’s trials in Q3 2025 following ...
The Pharma Letter
2 天
Positive Phase III result for opioid alternative cebranopadol
Tris Pharma reports positive Phase III data for cebranopadol, a dual-receptor agonist for acute pain, showing significant ...
The Pharma Letter
4 天
FDA accepts Replimune’s melanoma candidate for priority review
The US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for RP1 (vusolimogene ...
The Pharma Letter
4 天
Sarclisa gains European nod for first-line multiple myeloma
Sanofi secures EU approval for Sarclisa with VRd for newly diagnosed multiple myeloma patients ineligible for stem cell ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈